LAUSANNE, Switzerland, December 7, 2012 /PRNewswire/ --
Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that Dr. Reddy's Laboratories Ltd. launched Pamorelin ® LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer on December 3.
Under the terms of the agreement, Dr. Reddy's acquires exclusive marketing and sales rights for Pamorelin ® LA Depot in India. The product is exported in bulk from Debio Recherche Pharmaceutique (Debio R.P.) to Dr. Reddy's. Pamorelin ® LA will be made available primarily to urologists and oncologists across India.
'We recognise the need for prostate cancer treatment in India and are thrilled to have the opportunity to bring Pamorelin ® LA to Indian patients', said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. 'This major step enables us to implement our strategy in one of the most important markets in Asia. This is only the logical continuation to a harmonious working relationship shared with Dr. Reddy's over the years.' Dr. Reddy's and Debiopharm share the same vision to bring high-quality and safe ethical products to the highest number of patients suffering from serious diseases in India.About Pamorelin® LA (active ingredient: triptorelin) Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). In 1982, Debiopharm signed a licensing agreement for triptorelin with Tulane University in the US. Debiopharm has then developed three slow-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1- and 3-month-formulations have been registered in most countries and are currently available under the names of Trelstar® in North America, Decapeptyl® /Pamorelin® in Europe and Latin America and from now on, of Pamorelin® in India. The 6-month-formulation has been registered and is available in Europe and the US. About Debiopharm Group™
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV